Story
Samsung Biologics to Acquire PolyPeptide for $1.8 Billion in GLP-1 Market Push
Summary
South Korean contract drugmaker Samsung Biologics has agreed to buy Swiss firm PolyPeptide Group in a $1.8 billion all-cash deal, expanding its footprint into the high-demand market for peptide-based medicines like GLP-1 obesity treatments.
Samsung Biologics Co Ltd (KS:207940) announced on Monday it will acquire Switzerland’s PolyPeptide Group AG (SIX:PPGN) in an all-cash transaction valued at approximately 1.46 billion Swiss francs ($1.8 billion). The move marks a significant strategic expansion for the South Korean contract drugmaker into the rapidly growing market for peptide-based therapies.
Deal Details
Under the terms of the agreement, Samsung Biologics will offer 44.31 Swiss francs per share. This represents a 6.1% premium to PolyPeptide's closing share price on the preceding Friday. The transaction is expected to close by the end of 2026, pending regulatory approvals and other standard closing conditions.
The deal has received strong backing from the Swiss firm. PolyPeptide's board of directors has unanimously recommended the offer, and shareholders representing about 55.65% of the company's shares have already committed to tender their holdings, according to the announcement.
Strategic Rationale
AdThe acquisition is designed to bolster Samsung Biologics' capabilities in producing peptide active pharmaceutical ingredients (APIs). The company specifically highlighted the rising global demand for GLP-1 agonists, a class of drugs widely used in popular obesity and metabolic disease treatments.
By acquiring PolyPeptide, Samsung Biologics will also gain a significant global manufacturing footprint. The deal includes PolyPeptide's facilities in Sweden, Belgium, France, the United States, and India, providing an immediate and geographically diverse expansion.
Market Reaction
Following the announcement, shares of Samsung Biologics fell 3.4% to 1,354,000 won in Seoul trading on Monday. However, the company's stock outperformed the broader South Korean market, as the KOSPI index dropped a steeper 4.1% during the same session.
Read next
More on Stocks
China's Offshore Trust Tax Deadline Poses Risk to Individual Stocks, BofA Warns
A new Chinese tax rule on offshore trusts could force shareholders of some U.S. and Hong Kong-listed firms to sell stock to meet an October 22 payment deadline, according to BofA Securities.
RBA Governor Bullock Flags Upside Inflation Risks Ahead of Rate Decision
Reserve Bank of Australia Governor Michele Bullock warned that high energy prices and strong domestic demand pose significant upside risks to inflation, reinforcing a hawkish outlook as the central bank's next policy meeting approaches.
Alibaba Unveils V900 AI Chip, Signaling Major Demand for Domestic Foundries
Alibaba has introduced its Zhenwu V900 AI accelerator, described as China's most powerful, signaling a significant increase in manufacturing demand for domestic foundries like SMIC as the tech giant plans a massive data center expansion.
Luxury Sector Faces Deepening Slowdown as Brands Look to Fashion Weeks for a Boost
Major luxury brands are staging elaborate runway shows in Milan and Paris to combat a worsening sales slump and growing investor anxiety, driven by shifting consumer spending and economic pressures.